Intellia 治療公司
US ˙ NasdaqGM ˙ US45826J1051

SecurityNTLA / Intellia Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership172,939 shares
Latest Disclosed Value $ 1,622,167
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series ownership in NTLA / Intellia Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 172,939 shares of Intellia Therapeutics, Inc. (US:NTLA) valued at $1,622,168 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 172,939 shares of Intellia Therapeutics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $2,341,594 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Intellia Therapeutics EC US45826J1051 172,939 0 0.00 1,622 31.98 0.0364
2025-05-28 2025-03-31 NP Intellia Therapeutics EC US45826J1051 172,939 6,694 4.03 1,230 -36.58 0.0295
2025-02-25 2024-12-31 NP Intellia Therapeutics EC US45826J1051 166,245 -22,272 -11.81 1,938 -49.97 0.0423
2024-11-26 2024-09-30 NP Intellia Therapeutics EC US45826J1051 188,517 19,256 11.38 3,874 2.27 0.0733
2024-08-26 2024-06-30 NP Intellia Therapeutics EC US45826J1051 169,261 13,499 8.67 3,788 -11.60 0.0771
2024-05-28 2024-03-31 NP Intellia Therapeutics EC US45826J1051 155,762 -4,884 -3.04 4,285 -12.52 0.0894
2024-02-26 2023-12-31 NP Intellia Therapeutics EC US45826J1051 160,646 11,038 7.38 4,898 3.55 0.1045
2023-11-28 2023-09-30 NP Intellia Therapeutics EC US45826J1051 149,608 -2,968 -1.95 4,731 -23.98 0.1234
2023-08-25 2023-06-30 NP Intellia Therapeutics EC US45826J1051 152,576 20,201 15.26 6,222 26.13 0.1476
2023-05-26 2023-03-31 NP Intellia Therapeutics EC US45826J1051 132,375 -886 -0.66 4,934 6.11 0.1314
2023-02-24 2022-12-31 NP Intellia Therapeutics EC US45826J1051 133,261 12,057 9.95 4,649 -31.45 0.1279
2022-11-25 2022-09-30 NP Intellia Therapeutics EC US45826J1051 121,204 4,707 4.04 6,783 12.49 0.1943
2022-08-25 2022-06-30 NP Intellia Therapeutics EC US45826J1051 116,497 8,037 7.41 6,030 -23.50 0.1665
2022-05-26 2022-03-31 NP Intellia Therapeutics EC US45826J1051 108,460 1,677 1.57 7,882 -37.58 0.1836
2022-02-25 2021-12-31 NP Intellia Therapeutics EC US45826J1051 106,783 2,373 2.27 12,626 -9.85 0.2738
2021-11-24 2021-09-30 NP Intellia Therapeutics EC US45826J1051 104,410 7,852 8.13 14,007 -10.41 0.3086
2021-08-26 2021-06-30 NP Intellia Therapeutics EC US45826J1051 96,558 13,370 16.07 15,634 134.17 0.3354
2021-05-27 2021-03-31 NP Intellia Therapeutics EC US45826J1051 83,188 4,714 6.01 6,676 56.42 0.1514
2021-02-25 2020-12-31 NP Intellia Therapeutics EC US45826J1051 78,474 -3,187 -3.90 4,269 162.97 0.1094
2020-11-25 2020-09-30 NP Intellia Therapeutics EC US45826J1051 81,661 7,404 9.97 1,623 4.04 0.0521
2020-08-27 2020-06-30 NP Intellia Therapeutics EC US45826J1051 74,257 6,106 8.96 1,561 87.27 0.0510
2020-06-01 2020-03-31 NP Intellia Therapeutics EC US45826J1051 68,151 8,453 14.16 833 -4.80 0.0341
2020-02-27 2019-12-31 NP Intellia Therapeutics EC 45826J105 59,698 4,413 7.98 876 18.56 0.0263
2019-11-27 2019-09-30 NP Intellia Therapeutics EC US45826J1051 55,285 55,285 738 0.0244
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.